A company called MariMed makes and sells special plants that help people feel better. They have made a lot of money recently, but their stocks are not worth as much as they could be. A man named Zuanic thinks that MariMed's stocks will go up in the future because they have a good plan and are growing fast. He also says that other similar companies are doing well and MariMed should do better too. Read from source...

- The title is misleading and sensationalized. It implies that MariMed is undervalued based on its wholesale revenue growth, but does not provide any evidence or analysis of the company's actual market value, competitive advantage, profitability, or future prospects.
- The article is written in a promotional tone and lacks objectivity and credibility. It uses phrases like "top marijuana brands", "driven by top marijuana brands", and "why is this weed stock undervalued?" without explaining what these terms mean or how they are measured or verified.
- The article relies heavily on quotes from analysts who have a vested interest in the company's success, such as Zuanic, who has a buy rating on MariMed and receives compensation for investment banking services. It also cites MSOS ETF and Jushi, which are competitors or partners of MariMed, without disclosing their relationships or potential conflicts of interest.
- The article does not provide any critical analysis or balance of the information presented. It only highlights the positive aspects of MariMed's performance and growth, while ignoring or downplaying the negative factors, such as its low market share, regulatory risks, legal disputes, debt levels, etc.
- The article ends with a promotional plug for an upcoming event where MariMed's CEO will be speaking, which creates a conflict of interest and suggests that the author is trying to influence readers to invest in the company or attend the event.